Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Sun Pharmaceutical Industries Ltd

SUNPHARMA.NS ✓ COMPLIANT ☆ Track — members

NSE · Healthcare · Pharmaceuticals ·

India Large Cap Analyst: BUY

Last Close

$19.50

▼ -0.21%

Market Cap $46.95B · Vol 1.18M

Key Metrics

P/E Ratio

37.81

FWD: 31.20

Market Cap

$46.95B

Large Cap

Div Yield

0.86%

Semi-annual dividend

EPS Growth

+3.38%

YoY

RSI (14)

41.93

Momentum

Beta

0.85

vs Market

52W High

$21.45

9.14% below

52W Low

$16.22

13.88% above

Volume

1.18M

Avg 1.77M

P/B

5.05

Price-to-book

ROE

16.42%

Return on equity

Free Float

44.39%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Sun Pharmaceutical Industries Ltd (SUNPHARMA.NS) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does SUNPHARMA.NS pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-2.87%

-4.29%

+4.18%

+2.66%

YTD

+8.22%

+16.79%

+42.18%

+139.73%

Financials & Valuation

TTM · Annual

Total Revenue	$6.26B
Net Income	$1.20B
Revenue Growth (YoY)	+10.46%
Gross Margin	71.05%
Operating Margin	23.25%
Net Profit Margin	19.03%
ROE	16.42%
ROA · ROIC	15.05% · 14.30%

P/E Ratio	37.81
Forward P/E (FY1)	31.20
PEG Ratio	25.18
P/S	7.21
P/B	5.05
P/FCF	45.62
EPS Growth	+3.38%
Outstanding Shares	2.40B

Technical Indicators

50-Day SMA	$20.23
200-Day SMA	$18.91
RSI (14)	41.93
Beta	0.85
52-Week High	$21.45
52-Week Low	$16.22

Volume Today	1.18M
Avg Daily Volume (30D)	1.77M
Relative Volume	0.66x
Volatility (10D)	23.21
Volatility (30D)	17.27
Free Float	44.39%

Analyst Consensus

BUY

Current Price $19.50

Mean Target $22.59

52W Low$16.22 52W High$21.45

Current

Target

$16.22 $21.45

Current Analyst target

+15.86% upside potential · 35 analysts

Identifiers

ExchangeNSE

FIGIBBG001S73WG0

ISININE044A01036

CountryIndia

Sub-IndustryGeneric Pharmaceuticals

Earnings DateNov 3, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

4578.T Otsuka Holdings Co., Ltd. -1.80% ZYDUSLIFE.NS Zydus Lifesciences Ltd -0.85% CIPLA.NS Cipla Ltd +0.75% RICHTER.BU Richter Gedeon Vegyeszeti Gyar Nyrt -0.72% 4528.T ONO PHARMACEUTICAL CO., LTD. -0.40%

Company Profile

Sun Pharmaceutical Industries Limited is an India-based specialty generic pharmaceutical company with a presence in specialty therapies, generics and consumer healthcare products. The Company's global specialty portfolio spans products in dermatology, ophthalmology, and onco-dermatologym, among others. The Company manufactures and markets a large basket of pharmaceutical formulations across chronic and acute therapies, including generic, branded generics, specialty and complex products, over-the-counter (OTC), antiretrovirals (ARV), Active Pharmaceutical Ingredients (API), and intermediates. Its portfolio spans multiple dosage forms, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids. Its marketed specialty portfolio includes Ilumya/ Ilumetri, Winlevi, Levulan Kerastick + BLU-U, Absorica LD, Odomzo, Cequa, and others. Its portfolio also includes UNLOXCYTTM, an anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma.